BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Novavax’s Mixed Day: Encouraging Combo Vaccine Data and EUA Update

  The FDA noted that the EUA application for Novavax’s COVID-19 shot may take a while to be resolved, citing an “incredibly complex review process.”

  April 21, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Ultragenyx, Mereo Embark on Key Osteogenesis Imperfecta Trial

  Ultragenyx and Mereo celebrated their first patient dosed in a Phase II/III study investigating the use of setrusumab as a treatment for osteogenesis imperfecta (OI).

  April 21, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  Orasis Eyes FDA Approval in Presbyopia After Successful Phase III Trial

  Orasis Pharmaceuticals announced that its eye drop candidate CSF-1 met all primary and key secondary endpoints in Phase III clinical trials. CSF-1 is intended to treat presbyopia.

  April 21, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Octant Scores $80M in Series B Funds, Partnership with BMS

  Octant announced an $80 million Series B financing round, a Deep Mutual Scanning (DMS) biopharma partnership with Bristol Myers Squibb and key appointments to its leadership.

  April 21, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Sanofi Strikes Deal With Mysterious Psychedelics Biotech Terran

  New York-based Terran Biosciences inked a deal with Paris-based Sanofi for two late-stage central nervous system (CNS) assets. Terran plans to advance them for neurological and psychological indications.

  April 21, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Ampio Stock Craters After FDA Rejects Trial Changes

  Ampio shares continue to fall following the company’s announcement that the FDA rejected proposed changes to a Phase III study of its treatment for osteoarthritis of the knee and other joints.

  April 21, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Roundup: COVID-19 Pneumonia and Dementia Risk, Prostate Cancer Advances - and Oreos

  COVID-19 continues to generate surprises, such as a possible link between dementia and severe COVID-19. Continue reading for that and more research stories.

  April 21, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  AstraZeneca Touts Evusheld’s Efficacy in High-Risk Patients

  Clinical results announced this week could expand COVID-19 prevention options for the immunocompromised and vaccine ineligible, as well as those that have already contracted COVID.

  April 21, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  Servier On Cusp on New Indication with Robust Data in IDH1-mutated AML

  Servier is poised to go to market soon after the Phase III trial of its proposed drug for leukemia closed with positive results.

  April 21, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Policy

  UK Workers Union Offers GSK Small Window to Avoid Strike

  British employees of pharma giant GlaxoSmithKline (GSK) have voted to strike against the company’s recent pay raise. The employees are backed by British labor union Unite.

  April 21, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh